Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 2,291 matching trials from the live ClinicalTrials.gov search.
Conditions
Human Immuno-deficiency Virus (HIV) Disease
Interventions
Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

NCT00219986
Conditions
HIV Infections
Interventions
Potent HAART during acute or early HIV-1 infection
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions
blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram
Procedure · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 80 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Influenza
Interventions
Oseltamivir Phosphate, ADS-8902
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more
Conditions
HIV Infections
Interventions
VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C), rAd5 env A, rAd5 env B, rAd5 env C, rAd5 gag-pol, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Conditions
HIV Infections
Interventions
Early Treatment with HAART, No treatment, HAART Treatment - standard care
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 24 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma

NCT01625169
Conditions
HIV
Interventions
Etravirine pharmacokinetics in breast milk and plasma
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Conditions
HIV Infections
Interventions
Saquinavir, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Conditions
HIV Infections
Interventions
LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
5
States / cities
Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
Conditions
Hepatitis C, HIV Infections
Interventions
telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
11
States / cities
Beverly Hills, California • San Diego, California • San Francisco, California + 8 more
Conditions
HIV-1 Infection
Interventions
3BNC117, Antiretroviral Treatment Interruption
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Conditions
Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation, Methadone, Buprenorphine, Naltrexone, Antiretroviral Treatment
Interventions
Methadone, Buprenorphine/naloxone, XR-Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimethoprim, Sulfamethoxazole, Leucovorin calcium
Drug
Lead sponsor
Lederle Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
HIV Seropositivity, Adherence, Medication
Interventions
MI sessions, TMQQ, Type of compensation
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Opiate Addiction
Interventions
Onsite treatment, Enhanced referral, Buprenorphine
Behavioral · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New York, New York • The Bronx, New York
Conditions
Harm Reduction, HIV Infections, Drug Use
Interventions
Biktarvy 50Mg-200Mg-25Mg Tablet, HIV care
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
HIV Infections
Interventions
Amprenavir/ritonavir, Saquinavir/ritonavir
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Etravirine, Ritonavir, Darunavir
Drug
Lead sponsor
Tibotec, Inc
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 19 more
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Efavirenz, Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more